The global epigenetics market was valued at $1,018.1 million in 2020, and is projected to reach $4,056.86 million by 2030, registering a CAGR of 14.8% from 2021 to 2030.
Epigenetics is a stream of genetics that involves study of cellular and physiological trait variations initiated by external or ecological aspects, which turn genes on and off and affect cellular ability to read genes without being affected by changes in genotype. Epigenetics itself means in addition to alterations in genomic sequence, which means it results into changes in an organism’s phenotype rather than genotype, wherein the underlying DNA or RNA sequence remains unchanged. Epigenetic alterations are essential for development as they are dynamic and change with respect to environmental stimuli. However, these changes can be stable and could be passed from one generation to another. Biology and genetic expressions of most organisms are affected by epigenetics, which makes it one of the most crucial fields of developmental genetics and molecular biology. Methylation, acetylation, phosphorylation, ubiquitylation, and sumolyation are some of the epigenetic mechanisms that have been discovered.
The epigenetics market is expected to grow significantly during the forecast period, owing to rise in incidences of cancer and surge in its application in other chronic diseases such as cardiovascular disorders, metabolic diseases, infectious diseases, and inflammatory diseases. Increase in R&D activities, surge in investments in R&D, growth in epigenetic applications for non-oncology diseases, and increase in partnership between academic, pharmaceutical, and biotechnology companies significantly drive the market growth. However, high cost of instruments and lack of trained professionals impede the market growth.
Furthermore, untapped potential of emerging markets provides lucrative opportunities to the market players. Moreover, rise in application of epigenetics processes underlying illness onset and progression has proven critical in recent years for creation of innovative early diagnostic and prognosis biomarkers for assessing patients and its utilization in precision medicine.
The epigenetics market is segmented on the basis of product, application, end user, and region. By product, it is divided into enzymes, kits, instruments, and reagents. The enzymes segment is further divided into DNA ligases, DNA polymerases, other DNA-modifying enzymes, acetylases, methyltransferases, other protein-modifying enzymes, reverse transcriptase, RNA ligases, and other RNA-modifying enzymes. The kits segment is further subdivided into ChIP sequencing kits, bisulfite conversion kits, whole genome amplification kits, 5-hmC & 5-mC analysis kits, and RNA sequencing kits, and others. The instrument segment is further categorized into mass spectrometers, next-generation sequencers, qPCRs, sonicators, and others. The reagents segment is further divided into antibodies, buffers, histones, magnetic beads, primers, and others.
On the basis of application, the market is segmented into oncology and non-oncology. The oncology segment is further sub segmented into solid tumors and liquid tumors. Non-oncology applications include metabolic diseases, infectious diseases, inflammatory diseases, cardiovascular diseases, and other applications. By end user, it is segmented into academic & government research institutes, pharmaceutical & biotechnology companies, and contract research organizations (CROs). By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major players profiled in the report are Abcam Plc., Active Motif, Inc., Agilent Technologies, Inc., Hologic Inc. (Diagenode), Illumina Inc., Merck KGaA (Merck Millipore), PerkinElmer, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., and Zymo Research.
Epigenetics is a stream of genetics that involves study of cellular and physiological trait variations initiated by external or ecological aspects, which turn genes on and off and affect cellular ability to read genes without being affected by changes in genotype. Epigenetics itself means in addition to alterations in genomic sequence, which means it results into changes in an organism’s phenotype rather than genotype, wherein the underlying DNA or RNA sequence remains unchanged. Epigenetic alterations are essential for development as they are dynamic and change with respect to environmental stimuli. However, these changes can be stable and could be passed from one generation to another. Biology and genetic expressions of most organisms are affected by epigenetics, which makes it one of the most crucial fields of developmental genetics and molecular biology. Methylation, acetylation, phosphorylation, ubiquitylation, and sumolyation are some of the epigenetic mechanisms that have been discovered.
The epigenetics market is expected to grow significantly during the forecast period, owing to rise in incidences of cancer and surge in its application in other chronic diseases such as cardiovascular disorders, metabolic diseases, infectious diseases, and inflammatory diseases. Increase in R&D activities, surge in investments in R&D, growth in epigenetic applications for non-oncology diseases, and increase in partnership between academic, pharmaceutical, and biotechnology companies significantly drive the market growth. However, high cost of instruments and lack of trained professionals impede the market growth.
Furthermore, untapped potential of emerging markets provides lucrative opportunities to the market players. Moreover, rise in application of epigenetics processes underlying illness onset and progression has proven critical in recent years for creation of innovative early diagnostic and prognosis biomarkers for assessing patients and its utilization in precision medicine.
The epigenetics market is segmented on the basis of product, application, end user, and region. By product, it is divided into enzymes, kits, instruments, and reagents. The enzymes segment is further divided into DNA ligases, DNA polymerases, other DNA-modifying enzymes, acetylases, methyltransferases, other protein-modifying enzymes, reverse transcriptase, RNA ligases, and other RNA-modifying enzymes. The kits segment is further subdivided into ChIP sequencing kits, bisulfite conversion kits, whole genome amplification kits, 5-hmC & 5-mC analysis kits, and RNA sequencing kits, and others. The instrument segment is further categorized into mass spectrometers, next-generation sequencers, qPCRs, sonicators, and others. The reagents segment is further divided into antibodies, buffers, histones, magnetic beads, primers, and others.
On the basis of application, the market is segmented into oncology and non-oncology. The oncology segment is further sub segmented into solid tumors and liquid tumors. Non-oncology applications include metabolic diseases, infectious diseases, inflammatory diseases, cardiovascular diseases, and other applications. By end user, it is segmented into academic & government research institutes, pharmaceutical & biotechnology companies, and contract research organizations (CROs). By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major players profiled in the report are Abcam Plc., Active Motif, Inc., Agilent Technologies, Inc., Hologic Inc. (Diagenode), Illumina Inc., Merck KGaA (Merck Millipore), PerkinElmer, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., and Zymo Research.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the epigenetics market analysis from 2020 to 2030 to identify the prevailing epigenetics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the epigenetics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global epigenetics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
- Reagents
- Enzymes
- Instruments
- Kits
By Application
- Oncology
- Non Oncology
By End User
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- Contrac Research Organizations
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Middle East And Africa
- Latin America
Key Market Players
- Abcam Plc.
- Active Motif, Inc.
- Agilent Technologies, Inc.
- Hologic Inc.
- Illumina Inc.
- Merck Millipore
- PerkinElmer, Inc.
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
- Zymo Research
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: EPIGENETICS MARKET, BY PRODUCT
CHAPTER 5: EPIGENETICS MARKET, BY APPLICATION
CHAPTER 6: EPIGENETICS MARKET, BY END USER
CHAPTER 7: EPIGENETICS MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Executive Summary
The global epigenetics market was valued at $1.0 billion in 2020, and is estimated to reach $4.1 billion by 2030, growing at a CAGR of 14.8% from 2021 to 2030. Epigenetics is an area of developmental biology that involves study of cellular and physiological trait variations initiated by external or ecological aspects. This external stimulus turns genes 'on” and 'off” and affects ability of cells to read genes. Epigenetics changes phenotype of an organism rather than genotype, wherein the underlying DNA or RNA sequence remains unchanged. For instance, DNA methylation and histone modification are epigenetic processes wherein alteration in gene expression is observed without change in the DNA sequence. Increase in use and application of epigenetics to formulate drugs to treat different oncology and non-oncology-related diseases is expected to boost the market growth.Rise in cancer prevalence; increase in funding & aids for R&D activities; rise in partnership between academic, pharmaceutical, & biotechnology companies for epigenetics studies; and increase in application of epigenetics in non-oncology diseases majorly drives the market growth. In addition, various product launch, collaborations, and other developmental strategies among key players further drive the market.
For instance, in September 2021, Salarius Pharmaceuticals Inc., a clinical-stage biopharmaceutical firm investigating possible new medications for patients with sarcomas, pediatric malignancies, and other hematologic and solid tumors, announced a research collaboration with Fox Chase Cancer Center's Cancer Epigenetics Institute. The study is expected to aid in identification of additional indications and possible biomarkers for Salariu’s flagship medication candidate, seclidemstat. Thus, such research activities contribute toward growth of the market. However, high cost of instruments and lack of trained professionals are factors that impede the market growth. Conversely, growth opportunities in emerging markets provide lucrative opportunities to the market players.
On the basis of product, it is divided into enzymes, kits, instruments, and reagents. The kits segment generated maximum epigenetics market share revenue in 2020, accounting $394.62 million. The instruments for epigenetics market analysis segment is expected to witness highest CAGR of 16.3% during the forecast period.
On the basis of application, the market is classified into oncology and non-oncology. The oncology segment generated maximum revenue in 2020, accounting for685.53 million. The epigenetics market size for non-oncology segment is expected to witness highest CAGR of 15.3% during the forecast period.
By end user, it is segmented into academic & government research institutes, pharmaceutical & biotechnology companies, and contract research organizations (CROs). The pharmaceutical & biotechnology companies segment generated maximum revenue in 2020, accounting $534.53 million. The academic & government research institutes segment is expected to witness highest CAGR of 15.5% during the forecast period.
On the basis of region, the epigenetics market size of North America generated revenue worth $468.84 million in 2020, and is anticipated to dominate the global epigenetics market in the future. This is attributed to developed healthcare infrastructure, wide availability of advanced epigenetics products, large presence of key players, and presence of trained medical professionals. However, Asia-Pacific is expected to witness highest growth rate during the forecast period, owing to rise in awareness related to epigenetics industry, increase in penetration of key players in emerging countries in Asia-Pacific, and development in infrastructure for research and clinical settings.
Companies Mentioned
- Abcam Plc.
- Active Motif, Inc.
- Agilent Technologies, Inc.
- Hologic Inc.
- Illumina Inc.
- Merck Millipore
- PerkinElmer, Inc.
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
- Zymo Research
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 286 |
| Published | March 2022 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 1018.1 million |
| Forecasted Market Value ( USD | $ 4056.86 million |
| Compound Annual Growth Rate | 14.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
